Content area
Full text
Biopure Corporation has refuted the design of and the conclusions drawn by a meta-analysis conducted by Natanson et al that was recently published in JAMA."1
In a letter to the editor of JAMA, Dr A Gerson Greenburg from Biopure Corporation states that "there is neither statistical nor scientific basis for Natanson et al to assert there is a significantly increased risk of mortality associated with the use of HBOCs [haemoglobin-based oxygen carriers]".2 Dr Greenburg adds that the majority of experts at an FDA/NIH workshop investigating the safety of HBOCs "did not endorse the general conclusions of the analysis" and that the workshop recommended that...